New Monash biotech company receives funding to tackle cognitive disorders
A new Monash biotech company called Phrenix Therapeutics has received funding to advance research to develop new therapeutics for cognitive disorders, particularly in schizophrenia.
Treating mental illness with psychedelics - A Different Lens
In the fight for better mental health services, support and outcomes for millions of people around the world, the data can no longer be ignored: psychedelics might just be the key to unlocking a revolution in mental health.
Researchers discuss the psychedelic renaissance on 'What Happens Next?'
In this episode of What Happens Next?, Dr Susan Carland talks to Dr Paul Liknaitzky and Dr Meaghan O’Donnell.
NDC researchers featured on 'What Happens Next?' podcast episode on psychedelics
On a new episode of What Happens Next?, Susan Carland considers the political landscape surrounding drug legalisation, the cultural context of drug use and the promise of psychedelic therapy.
Monash University launches Neuromedicines Discovery Centre
Monash University today will launch an end-to-end, cross-disciplinary Centre to drive novel psychiatric drug discovery, as well as new approaches to neuromedicine-assisted psychotherapies, for the treatment of mental health disorders.